Fate Therapeutics (FATE) Reports Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune & Initiation of Phase 2 Stage
Tweet Send to a Friend
Fate Therapeutics, Inc. (NASDAQ: FATE) announced today Day 100 clinical data from the Phase 1 stage of its PROTECT clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
